

Figure S1. Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEB18, (B) MAGED3, (C) MAGED4, (D) MAGEE1 and (E) MAGEL2 for patients with the basal-like breast cancer subtypes (n=879). HR, hazard ratio; MAGE, melanoma-associated antigen.




Figure S2. Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEB6, (B) MAGEB18, (C) MAGED2, (D) MAGED4 and (E) MAGEE2 for patients with the luminal A breast cancer subtype (n=2,504). HR, hazard ratio; MAGE, melanoma-associated antigen.




Figure S3. Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEB6, (B) MAGED2, (C) MAGED4, (D) MAGEE2 and (E) MAGEF1 for patients with the luminal B breast cancer subtype (n=1,425). HR, hazard ratio; MAGE, melanoma-associated antigen.




Figure S4. Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEA5, (B) MAGEB4, (C) MAGEB6, (D) MAGEB18, (E) MAGED3, (F) MAGED4, (G) MAGEE1, (H) MAGEE2, (I) MAGEF1 and (J) MAGEL2 for patients with the HER2⁺ breast cancer subtype (n=1,425). HER2, human epidermal growth factor receptor 2; HR, hazard ratio; MAGE, melanoma-associated antigen.

